Publications by authors named "Terence Hall"

Claim this Profile
A
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.
Farhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, Guillermo Garcia-Manero, Musa Yilmaz, Terence Hall

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrostatic Dissipation in 3D-Printable Silicone.
Jeremy A Armas, Michael J Ford, Kenton P Foster, Terence Hall, Colin K Loeb

ACS Appl Mater Interfaces· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
Chiara Raggi, Karim Fiaccadori, Mirella Pastore, Margherita Correnti, Benedetta Piombanti, Terence Hall

Am J Pathol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, Christian Cotsoglou, William P Harris, Terence Hall

Br J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.
Lukas Balek, Iva Gudernova, Iva Vesela, Marek Hampl, Veronika Oralova, Terence Hall

Bone· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.
Terence G Hall, Yi Yu, Sudharshan Eathiraj, Yunxia Wang, Ronald E Savage

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Yi Yu, Terence Hall, Sudharshan Eathiraj, Michael J Wick, Brian Schwartz

Anticancer Drugs· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yi Yu, Ronald E Savage, Sudharshan Eathiraj, Justin Meade, Michael J Wick, Terence Hall

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Mark A Ashwell, Jean-Marc Lapierre, Christopher Brassard, Karen Bresciano, Cathy Bull, Terence Hall

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis